For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250630:nRSd0361Pa&default-theme=true
RNS Number : 0361P Venture Life Group PLC 30 June 2025
30 June 2025
VENTURE LIFE GROUP PLC
("Venture Life", "VLG" or the "Company")
Result of AGM
Venture Life (AIM: VLG), a leader in product innovation, development and
commercialisation within the global consumer healthcare sector, announces that
at the Annual General Meeting ("AGM") of the Company held at 10.00am today,
all resolutions proposed at the meeting were duly passed by shareholders.
Resolution 7 was withdrawn prior to the commencement of the AGM.
The full proxy results of the AGM will shortly be provided in the Investor
Relations section of the Company's website at www.venture-life.com/.
For further information, please contact:
Venture Life Group PLC +44 (0) 1344 578004
Jerry Randall, Chief Executive Officer
Daniel Wells, Chief Financial Officer
Cavendish Capital Markets Limited (Nomad and Broker) +44 (0) 20 7720 0500
Stephen Keys / George Lawson (Corporate Finance)
Michael Johnson (Sales)
About Venture Life (www.venture-life.com (http://www.venture-life.com/) )
Venture Life is an international consumer self-care company focused on
commercialising products for the global self-care market. Headquartered in the
UK, the Group's product portfolio includes Balance Activ in the area of
women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel
product ranges for energy and glucose management and hypoglycaemia, plus the
Health and Her product range supporting the hormonal lifecycle.
The products, which are typically recommended by pharmacists or healthcare
practitioners, are available primarily through health & beauty stores,
pharmacies, grocery multiples and e-commerce channels and are sold globally.
In the UK, Ireland and the USA these are supplied direct by the company to
retailers, elsewhere they are supplied by the Group's international
distribution partners.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END RAGURASRVAUNOAR